Navigation Links
Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results
Date:5/3/2011

oking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1031, LX1032, LX1033, LX2931, and LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Unless specifically indicated otherwise, results reported as trends were not statistically significant. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.Lexicon Pharmaceuticals, Inc.Selected Financial DataConsolidated Statements of Operations DataThree Months EndedMarch 31,(In thousands, except per share data)20112010(unaudited)Revenues:Collaborative research$  516$  1,641Subscription and license fees80-Total revenues5961,641Operating expenses:Research and development, inclu
'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Lexicon to Provide First Quarter 2011 Financial Results
2. Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
3. Lexicon Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
4. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results
5. Lexicon to Report Fourth Quarter and Year End 2010 Financial Results on February 24, 2011
6. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
7. Lexicon Pharmaceuticals to Present at the 29th Annual JPMorgan Healthcare Conference
8. Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
9. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2010 Financial Results
10. Lexicon Pharmaceuticals to Present at BioCentury Newsmakers in the Biotech Industry Conference Oct. 22nd
11. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 26, 2015 Research and Markets( http://www.researchandmarkets.com/research/rjpc7h/2015_strategies ... "2015 Strategies in the US Ancillary Hospital Locations ... to their offering. This new 973-page ... of the diagnostic testing markets outside the main ... includes analysis of the market dynamics, size, growth, ...
(Date:5/28/2015)... May 28, 2015  Freedom Meditech, Inc., a medical ... diseases from current blood-based standards to early and non-invasive ... million in a Series C financing. The company seeks ... million since founded. The company has also appointed Mr. ... a member of the company,s board of directors. Mr. ...
(Date:5/28/2015)... , May 28, 2015  According to Kalorama Information, ... Omnicare for approximately $12.7 billion fits a prevailing trend ... from an aging population. The U.S. long term care ... to continue as the aging population increases demand for ... The healthcare market researcher,s report, The Long Term ...
Breaking Medicine Technology:Strategies in the US Ancillary Hospital Locations (ERs, ORs, ICUs) Diagnostic Testing Market 2015-2020 2Freedom Meditech Raises $4.8 Million and Appoints John Gerace as Chief Executive Officer 2Freedom Meditech Raises $4.8 Million and Appoints John Gerace as Chief Executive Officer 3Freedom Meditech Raises $4.8 Million and Appoints John Gerace as Chief Executive Officer 4Kalorama: CVS Purchase of Omnicare Fits the Long Term Care Trend 2Kalorama: CVS Purchase of Omnicare Fits the Long Term Care Trend 3Kalorama: CVS Purchase of Omnicare Fits the Long Term Care Trend 4
... - Millennium on track to file sNDA in ... 18 Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ) ... large, international Phase III VISTA(1) trial in,patients with ... of,VELCADE, melphalan and prednisone (VMP) demonstrated a highly ...
... 10 minutes - - Landmark Study Reported in ... 18 A landmark publication that,appeared in the Journal ... site blinded clinical study. The paper is entitled "The ... Accuracy of,Melanoma and Equivocal Melanocytic Lesions." The study, ...
Cached Medicine Technology:Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints 2Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints 3Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints 4Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints 5Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints 6Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy 2Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy 3
(Date:5/28/2015)... (PRWEB) May 28, 2015 lifeIMAGE ... million round of financing led by Cambia Health ... company dedicated to transforming health care by creating a ... and most utilized network for exchanging medical imaging, will ... customer base, increase the breadth of its network capabilities ...
(Date:5/28/2015)... Cancer survivors who participated in the LIVESTRONG at ... and quality of life, according to research conducted by ... Ligibel, MD, senior physician in the Susan F. Smith ... findings will be presented at this year’s American ... Chicago. , The study, designed to assess ...
(Date:5/28/2015)... Ask not what your racquet can do for you ... your racquet. With the launch of their new digital campaign, ... astonishing tricks and unique skill to HEAD Pro Players and ... trick artist playfully demonstrates how to gain more control over ... but also challenges tennis enthusiasts everywhere to join the show. ...
(Date:5/28/2015)... 2015 The report “Dystonia – ... the therapeutic development for Dystonia. Dystonia is characterized ... often repetitive, movements, postures, or both. Dystonia affects ... backgrounds. The report strengthens R&D pipelines by identifying ... best-in-class products. Complete report on H1 2015 pipeline ...
(Date:5/28/2015)... UT—Dymicron, Inc., (dymicron.com) confirmed the successful completion of their ... disc replacement device. The two surgeries were performed by ... Institute of Minimally Invasive Surgery (AIMIS) in Cyprus. ... of the Dymicron devices,” said Dr. William D. Smith, ... for the University Medical Center, Las Vegas, Nevada. “The ...
Breaking Medicine News(10 mins):Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 2Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 3Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 4Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 2Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 3Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 4Health News:Tennis Artist Baffles Novak Djokovic - HEAD Launches Trick Shot Campaign “Frame & Play” 2Health News:Dystonia Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Dystonia Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Dystonia Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Dymicron, Inc., Announces the First Human Implantation of their Triadyme-CTM Cervical Total Disc Replacement Device in Cyprus 2
... embarks on one of its top priorities--reforming the nation,s health care ... of Health Care Reform, which will be announced during a media ... , ... Washington, DC (Vocus) February 6, 2009 -- As ...
... The Pink Frister on The Pacific Edge is set for ... Lucy, CEO of Code Pink Boot Camp, is pleased to ... event benefiting Fristers, a non-profit that supports teen and young ... 28 at 4:00pm at the Pacific Edge Hotel in Laguna ...
... "Psoriasis Cure Now," a nonprofit patient advocacy organization, ... help everyday Americans interested in medical research be heard ... powerful lobbyists and special interests. The Web site ... make biomedical research a meaningful part of any stimulus ...
... whether people were scanned or not , , FRIDAY, Feb. 6 ... low back pain that has no apparent underlying cause doesn,t ... that doctors should not conduct routine MRI, CT or radiography ... authors say. , Dr. Roger Chou, of the Oregon Health ...
... skepticism correlate with lower cancer screening rates , , FRIDAY, ... women, have more distrust of the medical system, which ... research shows. , Almost half of all women agreed ... health-care organizations." Eighteen percent strongly agreed with the statement. ...
... Institute for Palliative Medicine,s Fellowship Program received full accreditation ... -- the first accredited fellowship program in palliative medicine ... Diego Hospice, The Institute for Palliative Medicine has trained ... Medicine is known as one of the most clinically ...
Cached Medicine News:Health News:Pharmacy Stakeholder Groups Collaborate to Draft Pharmacy Principles for Health Care Reform 2Health News:Pharmacy Stakeholder Groups Collaborate to Draft Pharmacy Principles for Health Care Reform 3Health News:Code Pink Boot Camp Supports Fristers and Young Mothers 2Health News:Psoriasis Cure Now launches StimulateResearch.com to Ensure That Medical Research is Part of Stimulus Bill 2Health News:Imaging of Low Back Pain Fails to Change Outcomes 2Health News:Minorities Distrust Medical System More 2Health News:Minorities Distrust Medical System More 3Health News:San Diego Medical Community Receives First-Ever Accredited Palliative Medicine Fellowship Program 2Health News:San Diego Medical Community Receives First-Ever Accredited Palliative Medicine Fellowship Program 3
Straight shafts with micro Pierse type tips. Flat open serrated handle, dull finish....
Curved shafts with 0.5 mm, 1 x 2 teeth. Serrated handle with thumb catch lock and polished finish....
Jaws with fine teeth. Serrated handle with polished finish. Jaws: Wide, 4.5 mm. With thumb catch lock....
Straight shafts with curved 1 x 2 teeth. Serrated handle with polished finish....
Medicine Products: